EAU 2026: Updates in NMIBC
EAU 2026: Updates in NMIBC
Adding LAG-3 or TIGIT immunotherapy to enfortumab vedotin plus pembrolizumab does not improve outcomes in advanced UC
Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes in muscle-invasive bladder cancer
Cabozantinib plus nivolumab and ipilimumab improves response in low GDS mRCC while high GDS predicts worse survival
Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer
Circulating tumour DNA shows high accuracy for monitoring testicular cancer across all stages
Cabozantinib plus nivolumab and ipilimumab shows promising brain metastasis control in advanced kidney cancer
Belzutifan plus palbociclib shows modest activity with manageable safety in heavily pretreated kidney cancer
Circulating tumour DNA dynamics predict outcomes with pembrolizumab in advanced kidney cancer
HIF-2α inhibitor Cas shows durable responses and biomarker-linked benefit in metastatic kidney cancer
Pembrolizumab plus belzutifan improves disease-free survival in high-risk kidney cancer after surgery
Darolutamide improves progression-free survival across comorbidities in metastatic hormone-sensitive prostate cancer